Circuit Clinical, www.circuitclinical.com, one of the nation’s largest integrated research organizations dedicated to empowering patients to choose clinical research as a care option, announced a strategic partnership with CUBRC, a company specializing in advanced data analytics, information fusion and biomedical sciences. The agreement will combine both Circuit Clinical’s physician network and TrialScout, www.trialscout.com, a patient engagement platform, with CUBRC’s expertise in data sciences and the development and deployment of analytical software tools.
“This remarkable partnership completes Circuit Clinical’s comprehensive offering for creating and catalyzing the deep life science dataset that’s needed to drive the discovery of new medicines,” said Dr. Irfan Khan, CEO of Circuit Clinical. “With our foundational commitment to patient privacy and data ownership, our Physician Network partners and TrialScout already enable us to directly engage patients who are interested in donating their genomic and health data in a transparent and empowering manner. Our recently announced partnership with University at Buffalo Biorepository provides Circuit Clinical with the ability to sequence and store these donated biosamples. Now our collaboration with CUBRC will let us analyze all of the datasets we collect using a state-of-the-art HIPAA-compliant platform and an expert data science team as partners. This is a bold new approach for driving the discovery of new medicines.”
The strategic partnership is expected to:
CUBRC’s healthcare informatics team, led by Dr. John Coles, is collaborating with physicians, insurers, and medical device manufacturers to develop predictive analytic methods designed to improve patient outcomes while managing cost. “This partnership will enable CUBRC to apply its machine learning and artificial intelligence platforms to sets to provide high-confidence predictions of overall efficacy and individual patient response to new therapies.” said Mike Moskal, CUBRC’s CIO and Senior Vice President of the Information Exploitation Sector.
For more information, visit www.cubrc.org
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.